Resources

A collection of resources for the general public, health professionals and industry outlining a range of funding measures the Australian Government is taking to combat coronavirus (COVID-19).

This collection provides information about what inappropriate practice is, how it is identified, why it is important to conduct compliance on inappropriate practice, and commonly found compliance issues

This newsletter provides key health updates for Aboriginal and Torres Strait Islander households, communities and stakeholders.

Information on the new prescribed pattern of service 30/20 telephone rule, including relevant telephone attendance services. From 1 October 2022, GPs, Other Medical Practitioners and consultant physicians that claim relevant Medicare telephone items will be subject to the new rule.

This document answers some frequently asked questions the department has received from Commonwealth Home Support Programme (CHSP) service providers about Missing CHSP Client Migration process.

This document contains the surveillance case definition for Japanese encephalitis virus infection, which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This guideline can help you to substantiate Child Dental Benefits Schedule (CDBS) services that you have claimed or that have been claimed through your provider number. You must also show that consent to dental services and costs has been obtained and recorded.

A collection of newsletters sent out to subscribers featuring COVID-19 and vaccines updates and other health updates for Aboriginal and Torres Strait Islander communities.

A collection of resources for health professionals to help people with mucopolysaccharidosis type I (MPS I) access laronidase (Aldurazyme®) under the Life Saving Drugs Program.

A collection of resources for health professionals to help people with Fabry disease access the following drugs under the Life Saving Drugs Program: agalsidase alfa (Replagal®), agalsidase beta (Fabrazyme®) and migalastat (Galafold®).

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

This is an exposure draft of the proposed amendments to the Accountability Principles 2014 and Records Principles 2014 and the explanatory statement for these amendments. These amendments will support better provider governance and reporting arrangements.

An update from the Aboriginal and Torres Strait Islander Health Services Data Advisory Group (HS DAG) following their meeting in October 2022. It outlines the group's work across the Indigenous health data space.

This chart shows the types of services provided as part of the Commonwealth Home Support Programme (CHSP).

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This infographic explains when you can get your COVID-19 vaccination.

This data file contains statistical data about Australia's COVID-19 vaccinations.

This presentation, delivered on 20 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

Following the October Budget, the Commonwealth Home Support Programme (CHSP) has been extended until 30 June 2024. This fact sheet outlines what providers need to know about the 2023-24 Extension and associated program changes.

This 2022–2023 manual provides an overview of the Commonwealth Home Support Programme (CHSP), including the service types it funds and requirements for delivering those services. It is for CHSP-funded service providers to use, and forms part of their CHSP grant agreement.

This collection contains the National Notifiable Diseases Surveillance System (NNDSS) fortnightly reports. These reports provide a fortnightly summary on notifications of Australia’s nationally notifiable disease.